Coria LJJ, Rosales UE, Matías JNA, Juárez EM

Idioma: Español
Referencias bibliográficas: 34
Paginas: 185-192
Archivo PDF: 86.92 Kb.

RESUMEN

Las infecciones virales son causa elevada de morbilidad y mortalidad en los niños, particularmente en aquéllos inmunocomprometidos. La atención hospitalaria de estos pacientes, sea por su infección viral o por alguna complicación bacteriana, representa una erogación significativa para su tratamiento. Los pacientes inmunocomprometidos, son más susceptibles a padecer una infección viral más severa o diseminada. En esta comunicación se describe la indicación y el uso de antivirales, principalmente por agentes virales de la familia herpesvirus y algunos virus respiratorios, que son causa de consulta frecuente en pediatría, con el objeto de revisar los agentes antivirales que pueden ser empleados en su manejo ambulatorio.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Center for Evidence Bases Medicine, Universidad de Oxford, http//cebm.jr2.ox.ac.uk/ebmisisnt.html, Mayo 2000.

2. Harrison ChJ. Antivirales other than for HIV therapy. Advan Pediatr 2000; 47: 335-94.

3. Whitley RJ. Approaches to therapy of viral infections. Adv Pediatr 1987; 34: 89-110.

4. Muñoz FM. Critical care in infectious diseases, part II: Antiviral agents in the critically ill child. Semin Pediatr Infect Dis 2000; 11: 35-42.

5. Straus ES. Introduction to herpesviridae. In: Mandell LG, Bennett EJ, Dolin R, eds. Principles and Practice of Infectious Diseases. 5th ed. Churchill Livingstone 2000: 1557-64.

6. Whitley RJ, Hutto C. Neonatal herpes, simplex virus infections. Pediatric Rev 1985: 7119-126.

7. Corey L. Herpes simplex virus. In: Mandell LG, Bennett EJ, Dolin R. (eds). Principles and Practice of Infectious Diseases. Churchill Livingstone, 5th ed. 2000: 1564-1580.

8. Coria LJJ, Juárez EM, Velazco AVH. Meningoencefalitis viral. Enfoque clínico. Rev Mex Pediatr 2001; 68: 252-9.

9. Crane N, Lerner A. Herpetic withhold. A manifestation of primary infection with herpes simplex virus type 1 and 2. J Infect Dis 1978; 137: 855-6.

10. Grose C. Varicella-zoster virus: Pathogenesis of primary infection. In: Arvin AM, Gershon AA, eds: Varicella-zoster virus: Virology and Clinical Practice. Cambridge, MA, Cambridge Press, 2000: 105-113.

11. Arvin AM. Antiviral therapy for varicella and herpes zoster. Semin Pediatr Infect Dis 2002; 13: 12-21.

12. Feldman S, Lott L. Varicella in children with cancer: Impact of antiviral therapy and prophylaxis. Pediatrics 1987; 80: 465-572.

13. Whitley RJ. Varicella-zoster virus infections. In: Galasso GJ, Whitley RJ, Merigan TC eds. Antiviral Agents and Viral Diseases of Man. New York, NY. Raven, 1990: 235-63.

14. Jackson MA, Burry VF, Olson LC. Complications of varicella requiring hospitalization in previously healthy children. Pediatr Inf Dis J 1992; 11: 441-5.

15. American Academy of Pediatrics. Committee on Infectious Diseases. Varicella-zoster infections, Red Book 2000: 624-638.

16. Caltenco RS, Field JC. Varicela. En: Gómez DB, Coria JJL (eds). Infectología Práctica en el Paciente Pediátrico. Ed. Corinter, México. 1ª ed. 2003: 188-191.

17. Gershon AA. Varicela-zoster virus: Prospects for control. Advanc Pediatr Infect Dis 1995; 10: 93-124.

18. Srabstein JC, Morris N, Larke B et al. Is there a congenital varicella syndrome? J Pediatr 1974; 84: 239-243.

19. Da Silva O, Ilammerbert O, Chance GW. Fetal varicella syndrome. Pediatr Infect Dis J 1990; 9: 854-855.

20. Crumpacker SC. Cytomegalovirs. In: Mandell LG, Bennett EJ, Dolin R. (eds.). Principles and Practice of Infectious Diseases. Churchill Livingstone, Philadelphia. Fifty Ed. 2000: 1586-1598.

21. Canpolat C, Culbert S, Gardner M et al. Ganciclovir prophylaxis for cytomegalovirus infection in pediatric allogeneic bone marrow transplant recipients. Bone Marrow Transplant 1996; 17: 589-593.

22. Couchoud C, Cucherat M, Haugh M et al. Cytomegalovirs prophylaxis with antiviral agents in solid organ transplantation: A meta analysis. Transplantation 1998; 65: 641-647.

23. Nigro G, Krzysztofiak A, Bartmann U et al. Ganciclovir for cytomegalovirus associated liver disease in immunocompetent or immunocompromised children. Arch Virol 1997; 142: 573-580.

24. Schooley TR. Epstein-Barr virus (Infectious mononucleosis). In: Mandell LG, Bennett FJ, Dolin R. (eds). Principles and Practice of Infectious Diseases. Churchill Livingstone, Philadelphia. Fifty Ed. 2000: 1599-1613.

25. Kaiser L, Couch RB, Galasso GJ et al. First International Symposium on Influenza and Other Respiratory Viruses: Summary and overview. Kapalua, Maui, HI, December 4-6, 1998. Antiviral Res 1999; 42: 149-176.

26. Breese CH. Respiratory syncytial virus and parainfluenza virus. NEJM 2001; 344: 25: 1917-1828.

27. Johnston SL, Pattermore PK, Sanderson G et al. Community study of role of viral infection in exacerbations of asthma in 9-11 year old children. BMJ 1995; 310: 1225-1229.

28. González SN, Saltigeral SP. Antivirales. En: González SN, Saltigeral eds. Antimicrobianos, Antivirales, Antiparasitarios, Antimicóticos e Inmunomoduladores. 5ª ed. México: McGraw-Hill 2001: 210-229.

29. Kimberlin WD. Acyclovir derivates and other new antiviral agents. Semin Pediatr Infect Dis 2001; 12: 224:34.

30. Wood JA. Drug therapy. Acyclovir: A decade later. NEJ 1992; 327(11): 782-7.

31. Prober ChG. Antiviral therapy for influenza virus infections. Semin Pediatr Infec Dis 2002; 13: 31-9.

32. Lin TZ, Huang YCh, Ning HCh, Hsueh Ch. Oral acyclovir prophylaxis of varicella after intimate contact. Pediatr Infect Dis J 1997; 16(12): 1162-1165.

33. Kumagai T, Kamada M, Igarashi Ch, Yuri K, Furukawa H, Chiba S et al. Varicella-zoster virus-specific cellular immunity in subjects given acyclovir after household chickenpox exposure. J Infect Dis 1999; 180: 834-7.

34. White ChB, Hawley WZ, Harford DJ. The pediatric resident susceptible to varicella: Providing immunity through postexposure prophylaxis with oral acyclovir. Pediatr Infect Dis J 1994; 13: 743-4.